Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

21 Sökresultat.
Relevans Bedömning Nya först Gamla först

UKHD - Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Verlaufsangaben

- 09/03/22 - 10 Formulär, 3 Item-grupper, 38 Dataelement, 1 Språk
Item-grupper: Verlaufsangaben, Präoperative Vorbereitung - Checkliste, OP und Verlauf
Routinedokumentation der Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Multimodale Brustdiagnostik. Sektionsleiter Senologie: Prof. Dr. med. Jörg Heil, MHBA

Empfehlung des postoperativen Tumorboards

1 Item-grupp 26 Dataelement

Poststationäre Ergänzungen

1 Item-grupp 2 Dataelement

Pathologie

3 Item-grupper 121 Dataelement

Procedere

1 Item-grupp 27 Dataelement

Follow Up Status AML UKM

- 27/09/21 - 1 Formulär, 6 Item-grupper, 21 Dataelement, 2 Språk
Item-grupper: Administrative Data, Diagnoses, Therapies/Procedures, Further details, Relapses, Further Comments
Routine documentation of University Hospital Muenster. Unit: Hematology and Internistic Oncology. Based on items of original form: FollowUp Tumornachsorge MS

German Quality Management KVWL - dataset KVWL

- 27/09/21 - 1 Formulär, 8 Item-grupper, 98 Dataelement, 2 Språk
Item-grupper: Patient data, Diagnosis, Follow up, Autopsy, Tumor Expansion, Histopathology, Staging, Distant metastasis
quality management dataset German Quality Management Onkologische Qualitätssicherung der Kassenärztlichen Vereinigung Westfalen-Lippe" (OQSWL)

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314 - Therapy and toxicity cycle 10-13

- 20/09/21 - 16 Formulär, 16 Item-grupper, 68 Dataelement, 1 Språk
Item-grupper: Therapy cycle 10-13, Therapy after cycle, Propranolol, Propranolol therapy deviation, Celecoxib, Celecoxib deviation, Cyclophosphamide, Cyclophosphamide deviation, Vinblastine, Vinblastine deviation, Toxicity overview, Toxicity, Hospitalization, Comments, Transfusion, Footer module
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Therapy and toxicity cycle > 13

16 Item-grupper 68 Dataelement

Therapy and toxicity cycle 1-3

16 Item-grupper 68 Dataelement

Therapy and toxicity cycle 4-6

16 Item-grupper 68 Dataelement

Therapy and toxicity cycle 7-9

16 Item-grupper 68 Dataelement

Baseline

13 Item-grupper 77 Dataelement

Reference

12 Item-grupper 111 Dataelement

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Zytoreduktive Chirurgie / HIPEC Part 2

- 02/09/21 - 1 Formulär, 7 Item-grupper, 65 Dataelement, 1 Språk
Item-grupper: Administrative Documentation, Postoperative questions, Result of Surgery, Pathological tumor staging, Tumor staging, HIPEC, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Woche 12

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Baseline - Physical Examination; Laboratory Results; Disease Staging

- 25/03/21 - 1 Formulär, 14 Item-grupper, 55 Dataelement, 1 Språk
Item-grupper: Administrative, Physical Examination (Baseline), Physical Examination (Baseline) , Laboratory Results (Baseline) - Hematology, Laboratory Results (Baseline) - Hematology, Laboratory Results (Baseline) - Chemistry, Laboratory Results (Baseline) - Chemistry, Pregnancy Test (Baseline), Disease Staging - CT or other Radiological Imaging Results (Baseline), Disease Staging - Bone Marrow Biopsy (Baseline), Disease Staging - Measurable Lymphoma Disease (Baseline), Disease Staging - Non-Measurable Lymphoma Disease (Baseline) , Disease Staging - Non-Measurable Lymphoma Disease (Baseline) , Signature of Investigator
Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Response Assessment

- 20/08/19 - 1 Formulär, 4 Item-grupper, 12 Dataelement, 1 Språk
Item-grupper: Administrative documentation, TNM clinical staging, Rectal Carcinoma, Pathological staging, Rectal Carcinoma, Sphincter, Preservation technique
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

German Hodgkin Study Group Study HD16/HD17/HD18 Restaging G6RE DRKS00003455 DRKS00003457 - Deutsche Hodgkin Studiengruppe: G6RE Restagingbogen

- 14/11/18 - 1 Formulär, 8 Item-grupper, 68 Dataelement, 1 Språk
Item-grupper: Form Header, Laboratory, Nodal involvement, Organ involvement, Lymph node size after Chemotherapy, Examinations, Best response, Comments
HD16 NCT Nr.: NCT00736320 HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET. This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS). HD17 NCT Nr.: NCT01356680 HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma.This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS). HD18 NCT Nr.: NCT00515554 HD18 for Advanced Stages in Hodgkins Lymphoma. This study is designed to test: in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS. Permission granted by: Andreas Engert, M.D. Chairman, German Hodgkin Study Group Professor for Internal Medicine Hematology & Oncology University Hospital of Cologne Department of Internal Medicine I Kerpener Str. 62 D-50924 Köln Phone: +49-221-478-5933/5966 Fax: +49-221-478-3778 a.engert@uni-koeln.de

German Hodgkin Study Group Study HD16/HD17/HD18 Staging G6E DRKS00003457 DRKS00003455 - Deutsche Hodgkin Studiengruppe: G6E Erhebungsbogen

- 01/11/18 - 1 Formulär, 9 Item-grupper, 108 Dataelement, 1 Språk
Item-grupper: Form Header, Nodal involvement, Organ involvement, Examinations, MRI instead of CT, Other examinations, Risk factors, Ann-Arbor Staging, Comments
HD16 NCT Nr.: NCT00736320 HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET. This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS). HD17 NCT Nr.: NCT01356680 HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma.This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS). HD18 NCT Nr.: NCT00515554 HD18 for Advanced Stages in Hodgkins Lymphoma. This study is designed to test: in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS. Permission granted by: Andreas Engert, M.D. Chairman, German Hodgkin Study Group Professor for Internal Medicine Hematology & Oncology University Hospital of Cologne Department of Internal Medicine I Kerpener Str. 62 D-50924 Köln Phone: +49-221-478-5933/5966 Fax: +49-221-478-3778 a.engert@uni-koeln.de

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Disease Staging - Baseline

- 12/07/18 - 1 Formulär, 9 Item-grupper, 35 Dataelement, 1 Språk
Item-grupper: Administrative Data, Diagnostic Imaging, Head/Neck, Diagnostic Imaging; Chest, Diagnostic Imaging, Abdomen, Diagnostic Imaging, Pelvis, Diagnostic Imaging, Other, Bone Marrow Biopsy, Measurable Lymphoma Disease, Non-Measurable Disease
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy NCT00989664 - Disease Staging and Laboratory Tests

- 22/05/18 - 1 Formulär, 6 Item-grupper, 34 Dataelement, 1 Språk
Item-grupper: CT or other Radiological Imaging Results, Bone Marrow Biopsy, Measurable Lymphoma Disease, Non-Measurable Dlsease, Administration, Laboratory Results
Disease Staging and Laboratory Tests Study ID: 104504 Clinical Study ID: BEX104504 Study Title: Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00989664 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Breast Cancer Swedish National Quality Registry - Report

- 07/02/18 - 1 Formulär, 7 Item-grupper, 43 Dataelement, 2 Språk
Item-grupper: National Quality Register for Breast Cancer, Report, Hospital, Diagnosis, Menstruation Status, TNM Classification, Care planning, Pathology from intervention / needle core biopsy
Description of registry: The aim of the National Quality Registry for Breast Cancer is to: -in an objective and standardised manner, monitor the continuum of care from diagnosis to any recurrence and death -enable the identification of regional differences -collectively relate to current guidelines and quality targets set by specialist associations and the National Board of Health and Welfare -facilitate research and developments in breast cancer. Report Source: http://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/dokument/ Facts Owner: Kerstin Sandelin surgeon, Karolinska University Hospital, Solna kerstin.sandelin@sll.se

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial